Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 10, 2007New England Journal of MedicineOpen Access

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

Daniel F. Hayes
Daniel F. HayesIntermountain HealthcareATAnn D. ThorBoston UniversityLDLynn G. DresslerUniversity of North Carolina at Chapel Hill

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hayes et al. (2007) studied this question.

synapsesocial.com/papers/6a0bb3c8aab637ffb5c1ff6bhttps://doi.org/10.1056/nejmoa071167
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Relation between Estrogen Receptors and Response Rate to Cytotoxic Chemotherapy in Metastatic Breast Cancer1978 · 284 citations
  2. 2Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy2005 · 1,912 citations
  3. 3Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene1987 · 11,839 citations
  4. 4Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer2006 · 736 citations
  5. 5Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer2003 · 1,307 citations